2021-01-07,Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies
2021-01-05,Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
2020-12-14,Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares
2020-12-09,Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million
2020-12-09,Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering
2020-12-07,Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
2020-11-30,Is Oncternal Therapeutics (ONCT) A Good Stock To Buy Now?
2020-11-17,Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 Million
2020-11-17,Oncternal Therapeutics Announces $20.0 Million Bought Deal Offering
2020-11-11,Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2020 Virtual Annual Meeting
2020-11-10,"Is Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Popular Amongst Insiders?"
2020-11-09,Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference
2020-11-04,Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update
2020-10-06,Oncternal Therapeutics Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TK216 for Treatment of Ewing Sarcoma
2020-09-22,Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
2020-09-21,Oncternal Therapeutics Announces Presentation of Interim Phase 1 Clinical Trial Data for TK216 in Patients with Relapsed/Refractory Ewing Sarcoma at ESMO Virtual Congress 2020
2020-09-10,Oncternal Therapeutics to Participate in September Investor Conferences
2020-09-03,"The Independent Director of Oncternal Therapeutics, Inc. (NASDAQ:ONCT), Michael Carter, Just Bought 13,789% More Shares"
2020-08-27,Oncternal Therapeutics Increases Previously Announced Bought Deal to $4.5 Million
2020-08-27,Oncternal Therapeutics Announces $3.5 Million Bought Deal Offering
2020-08-06,Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results
2020-08-06,Oncternal Therapeutics'(NASDAQ:ONCT) Share Price Is Down 33% Over The Past Year.
2020-07-30,Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update
2020-07-27,Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma
2020-07-20,Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
2020-06-30,Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia
2020-06-30,Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma
2020-05-20,Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
2020-05-19,Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting
2020-05-07,Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results
2020-05-05,Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update
2020-05-01,Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update
2020-03-18,Is Oncternal Therapeutics (NASDAQ:ONCT) In A Good Position To Invest In Growth?
2020-03-16,Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results
2020-03-11,Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update
2020-03-11,"Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma"
2020-02-06,Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
2019-12-12,Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium
2019-12-11,"Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma"
2019-12-09,Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting
2019-12-03,Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium
2019-11-21,Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference
2019-11-14,"Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting"
2019-11-11,Oncternal Therapeutics to Present at Stifel Healthcare Conference
2019-11-07,Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update
2019-11-05,Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting
2019-10-31,Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update
2019-10-03,Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
2019-09-20,We're Not Very Worried About Oncternal Therapeutics's (NASDAQ:ONCT) Cash Burn Rate
2019-09-17,Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Childrens Oncology Group Meeting
2019-09-09,"Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer"
2019-08-28,"Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing"
2019-08-08,Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update
2019-08-06,Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib
2019-08-01,Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
2019-06-10,"Oncternal Therapeutics Completes Reverse Merger with GTx, Inc."
